Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 415-423 , May 2007

Biodistribution, pharmacokinetics and imaging of 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model

  • Liang-Cheng Chen

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Chih-Hsien Chang

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Chia-Yu Yu

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Ya-Jane Chang

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Wei-Chuan Hsu

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Chung-Li Ho

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Chung-Hsin Yeh

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Tsai-Yueh Luo

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Te-Wei Lee

      Affiliations

    • Institute of Nuclear Energy Research, Taoyuan, Taiwan
    • ,
  • Gann Ting

      Affiliations

    • National Health Research Institutes, Miaoli, Taiwan
    • Corresponding Author InformationCorresponding author. National Institute of Cancer Research, National Health Research Institutes, A191Ward, Veterans General Hospital-Taipei 201, Sec. 2, Beitou Taipei 112, Taiwan, ROC. Tel.: +886 2 28712121; fax: +886 2 28716467.

Received 3 November 2006 ,Revised 16 January 2007 ,Accepted 8 February 2007.

References 

  1. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–1822
  2. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145–160
  3. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 1992;52:5135–5143
  4. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, Friend DS. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol. 1993;143:10–14
  5. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43:1–7
  6. Vaage J, Donovan D, Wipff E, Abra R, Colbern G, Uster P, et al. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer. 1999;80:134–137
  7. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419–436
  8. Eisenberg B, Decosse JJ, Harford F, Michalek J. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer. 1982;49:1131–1144
  9. Sood R. Ascites: diagnosis and management. JIACM. 2000;5:81–89
  10. Markman M. Intraperitoneal chemotherapy in the management of colon cancer. Semin Oncol. 1999;26:536–539
  11. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum. 2000;43:1341–1346
  12. Syrigos KN, Vile RG, Peters AM, Harrington KJ. Biodistribution and pharmacokinetics of 111In-dTPA-labelled pegylated liposomes after intraperitoneal injection. Acta Oncol. 2003;42:147–153
  13. Speyer JL. The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol. 1985;12:23–28
  14. Delgado G, Potkul RK, Treat JA, Lewandowski GS, Barter JF, Forst D, et al. A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am J Obstet Gynecol. 1989;160:812–817
  15. Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res. 1998;4:499–505
  16. Vaage J, Donovan D, Mayhew E, Abra R, Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer. 1993;72:3671–3675
  17. Sadzuka Y, Hirota S, Sonobe T. Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination. Toxicol Lett. 2000;116:51–59
  18. Emfietzoglou D, Kostarelos K, Sgouros G. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med. 2001;42:499–504
  19. Emfietzoglou D, Kostarelos K, Papakostas A, Yang WH, Ballangrud A, Song H, et al. Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody. J Nucl Med. 2005;46:89–97
  20. Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, et al. Biodistribution and therapeutic efficacy of 125/131I-, 186Re-, 88/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med. 2004;45:1224–1232
  21. Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C, et al. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer. 1995;31A:686–690
  22. Iznaga-Escobar N. 188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology. Nucl Med Biol. 1998;25:441–447
  23. Bao A, Goins B, Klipper R, Negrete G, Phillips WT. 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med. 2003;44:1992–1999
  24. Tseng YL, Hong RL, Tao MH, Chang FH. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer. 1999;80:723–730
  25. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466–468
  26. Hsieh BT, Callahan AP, Beets AL, Ting G, Knapp FF. Ascorbic acid/saline eluant increases 188Re yields after “wet” storage of 188W/188Re generators. Appl Radiat Isot. 1996;47:23–26
  27. Reilly RM, Chen P, Wang J, Scollard D, Cameron R, Vallis KA. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med. 2006;47:1023–1031
  28. Chang CH, Wang HE, Wu SY, Fan KH, Tsai TH, Lee TW, et al. Comparative evaluation of FET and FDG for differentiating lung carcinoma from inflammation in mice. Anticancer Res. 2006;26:917–925
  29. Hafeli U, Tiefenauer LX, Schbiger PA, Weder HG. A lipophilic complex with 186Re/188Re incorporated in liposomes suitable for radiotheraphy. Int J Rad Appl Instrum. 1991;18:449–454
  30. Kostarelos K, Emfietzoglou D. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals. Anticancer Res. 2000;20:3339–3345
  31. Mc Quarrie S, Mercer J, Syme A, Suresh M, Miller G. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Sci. 2005;7:29–34
  32. Kutzner J, Becker M, Grimm W. Bone-seeking behavior of rhenium and yttrium complexes. Nuklearmedizin. 1983;22:162–165
  33. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol. 1994;34:137–146
  34. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992;52:891–896
  35. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 1982;42:1412–1422
  36. Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice. Pharm Res. 1996;13:861–868
  37. Harding JA, Engbers CM, Newman MS, Goldstein NI, Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta. 1997;1327:181–192
  38. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732–6740
  39. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545–580
  40. Chang CH, Jan ML, Fan KH, Wang HE, Tsai TH, Chen CF, et al. Longitudinal evaluation of tumor metastasis by an FDG-microPET/microCT dual-imaging modality in a lung carcinoma-bearing mouse model. Anticancer Res. 2006;26:159–166

PII: S0969-8051(07)00042-X

doi: 10.1016/j.nucmedbio.2007.02.003

Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 415-423 , May 2007

Article Tools

* Image Usage & Resolution